N/A Completed N=36 Randomized Triple-blind Prevention

ADAM17 and Vascular Function in Diabetes

Diabetes Mellitus, Type 2

Source: ClinicalTrials.gov NCT04557228 ↗

Enrolled (actual)

Serious AEs

11.1%

Results posted

May 2026

Primary outcomePrimary: Change in Insulin-stimulated Blood Flow — -70.80; 24.79 mL/min

Summary

The objective of this project is to determine the extent to which administration of the dietary supplement phosphatidylserine (PS), a competitive inhibitor of ADAM17 sheddase activity, effects vascular function and insulin-stimulated leg blood flow in subjects with T2D.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Insulin-stimulated Blood Flow	-70.80; 24.79	—
SECONDARY Percent Change in Vascular Function	0.54; 0.41	—

Eligibility Criteria

Inclusion Criteria

Men and women with a BMI of 25-39 kg/m2, who are 45-64 years of age at randomization.
T2D patients classified based on physician diagnosis.
No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.

Exclusion Criteria

Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
History of chronic renal or hepatic disease
Active cancer
Autoimmune diseases
Immunosuppressant therapy
Hormone replacement therapy
Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
Current tobacco use
Pregnancy
Bodyweight change ≥5% within the last 6 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04557228). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.